Cross-Sector entity
Of the tracked stories, 4 of 5 also mention Vertex Pharmaceuticals, the most common co-covered peer. That works out to roughly 0.3 stories per week across a 134-day span. The busiest single day carried 2. Coverage clusters in gene-therapy, which accounts for 2 of those 5, with the remainder spread across 3 other categories.
5 verified stories tracked
Last mentioned: Jul 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 60 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 5 also mention Vertex Pharmaceuticals, the most common co-covered peer. That works out to roughly 0.3 stories per week across a 134-day span. The busiest single day carried 2. Coverage clusters in gene-therapy, which accounts for 2 of those 5, with the remainder spread across 3 other categories. Each carries 9.2 original sources on average. Negative sentiment appears in 0% of the tracked stories. CRISPR Therapeutics appears in 5 tracked Cross-Sector stories published from February 26, 2026 through July 9, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CRISPR Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Offering Upsized
The company prices an upsized $550M offering due to strong institutional interest.
ARK Invest Trade
Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
Debt Offering Announced
CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
Cure Announcement
Medical officials formally announce the patient is cured, marking a global first for gene editing technology.
Six-Month Follow-up
Clinical evaluations confirm significant biological markers of recovery and the absence of off-target effects.
Therapy Administration
A one-time gene editing intervention is administered at a specialized pediatric facility in British Columbia.
Trial Enrollment
The B.C. teen is enrolled in a world-first experimental gene editing clinical trial for a rare genetic disorder.
The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Source: wdov.iheart.com · kogo.iheart.com
ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
Source: seekingalpha.com · Seeking Alpha
A British Columbia teenager has achieved a historic medical milestone, becoming the first person globally to be cured of a rare genetic disease using advanced gene editing technology. This breakthrough marks a definitive shift in the treatment of rare disorders, moving from chronic management to a potential one-time curative intervention.
Source: theprovince.com · theprovince.com
